Strategic Advocates’s Bio-Techne TECH Stock Holding History

Strategic Advocates’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16	Closed	-$946	–	574
2025 Q4	$946	Hold	16	–	–	﹤0.01%	520
2025 Q3	$890	Buy	+16	New	+$857	﹤0.01%	503

Other funds holding TECH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Strategic Advocates's TECH Position: Q1 2026 in Review

Strategic Advocates sold out of Bio-Techne (TECH) in Q1 2026, closing a stake of 16 shares — an estimated $946 sold.

Strategic Advocates first reported a position in TECH in Q3 2025 and held it in 2 quarters. The position peaked at $946 in Q4 2025. 582 funds tracked by Wall St. Rank hold TECH as of Q1 2026.

Strategic Advocates reported no remaining Bio-Techne position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 16 Bio-Techne shares in Q1 2026, an estimated $946.
Strategic Advocates first reported a position in Bio-Techne in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Bio-Techne position peaked at $946 in Q4 2025.
582 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.